This company has been marked as potentially delisted and may not be actively trading.

Amicus Therapeutics (FOLD) Stock Forecast & Price Target

Get the Latest News and Ratings for FOLD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FOLD Analyst Ratings Over Time

Type	Current Forecast 5/14/25 to 5/14/26	1 Month Ago 4/14/25 to 4/14/26	3 Months Ago 2/13/25 to 2/13/26	1 Year Ago 5/14/24 to 5/14/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$14.56	$15.39	$15.55	$16.22
Forecasted Upside	0.50% Upside	6.42% Upside	8.67% Upside	175.89% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

FOLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FOLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amicus Therapeutics Stock vs. The Competition

Type	Amicus Therapeutics	Medical Companies	Broader Market
Consensus Rating Score	2.08	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	0.50% Upside	1,814.29% Upside	17.12% Upside
News Sentiment Rating	Positive News See Recent FOLD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
3/27/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
1/26/2026	Zacks Research Not Rated		Downgrade	Strong-Buy ➝ Hold
1/22/2026	Jefferies Financial Group 2 of 5 stars	Dennis Ding Not Rated	Reiterated Rating	Buy ➝ Hold	$16.00 ➝ $14.50	+1.05%
1/5/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
12/29/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$17.00 ➝ $14.50	+1.75%
12/22/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$14.50	+2.14%
12/22/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samantha Semenkow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$17.00 ➝ $14.50	+2.14%
12/19/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
12/19/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kristen Kluska Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Hold	$21.00 ➝ $14.50	+1.86%
11/6/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anupam Rama Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$18.00 ➝ $19.00	+113.48%
Get the Latest News and Ratings for FOLD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/5/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$9.00 ➝ $11.00	+18.74%
7/17/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Hung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
5/2/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Karl Chalabala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$21.00 ➝ $22.00	+229.83%
2/20/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tiago Fauth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$18.00 ➝ $17.00	+77.82%
10/17/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$13.00 ➝ $15.00	+24.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:12 PM ET.

FOLD Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Amicus Therapeutics is $14.56, with a high forecast of $19.00 and a low forecast of $11.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There is currently 1 sell rating, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FOLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.

According to analysts, Amicus Therapeutics's stock has a predicted upside of 0.50% based on their 12-month stock forecasts.

Amicus Therapeutics has been rated by research analysts at Weiss Ratings in the past 90 days.

Analysts like Amicus Therapeutics less than other "medical" companies. The consensus rating score for Amicus Therapeutics is 2.08 while the average consensus rating score for "medical" companies is 2.30. Learn more on how FOLD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Amicus Therapeutics Recommendations

This page (NASDAQ:FOLD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.